Literature DB >> 16272187

Individual differences in aggressive responding to intravenous flumazenil administration in adult male parolees.

Oleg V Tcheremissine1, Scott D Lane, Lori M Lieving, Howard M Rhoades, Sylvain Nouvion, Don R Cherek.   

Abstract

Nonhuman and human studies have shown that benzodiazepine (BZD) receptor agonists can modify aggressive behaviour. However, it is unknown whether flumazenil, a BZD receptor antagonist, enhances or inhibits aggressive behaviour. The present study was designed to investigate the effects of acute administrations of flumazenil on aggressive responding in adult humans. Six adult males with histories of childhood conduct disorder (DSM IV R) participated in experimental sessions. Aggression was measured using the Point Subtraction Aggression Paradigm (PSAP; Cherek 1992), which provided subjects with aggressive and monetary-reinforced response options. Acute doses of flumazenil (2 and 3mg) did not produce statistically significant changes in either monetary-reinforced responding or aggressive responding. The analysis of individual subjects data revealed that aggressive responses varied across subjects. The results are discussed in terms of individual differences based on the previous history of BZD abuse. Additional laboratory research is needed to better clarify the behavioural mechanisms by which BZD receptor antagonists modify human aggressive responding.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16272187     DOI: 10.1177/0269881105056532

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  2 in total

1.  Gabapentin Abuse in a Patient with Comorbid Mood and Substance Use Disorders.

Authors:  Oleg V Tcheremissine; Durga Prasad Bestha
Journal:  Innov Clin Neurosci       Date:  2016-08-01

2.  The neurobiological bases for development of pharmacological treatments of aggressive disorders.

Authors:  Allan Siegel; Suresh Bhatt; Rekha Bhatt; Steven S Zalcman
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.